Welcome to our dedicated page for Transmedics Group news (Ticker: TMDX), a resource for investors and traders seeking the latest updates and insights on Transmedics Group stock.
TransMedics Group, Inc. reports developments in medical technology for organ transplant therapy, centered on its Organ Care System, or OCS, for preserving and monitoring donor lungs, hearts and livers outside the body. Company updates commonly cover OCS utilization through the National OCS Program, transplant logistics services, aviation fleet capacity, revenue trends and margin drivers.
Recurring news also includes clinical and regulatory disclosures tied to OCS programs and the Controlled Hypothermic Organ Preservation System, tax-accounting updates, material agreements, governance actions and employee equity awards. These developments reflect the company's commercial-stage model in organ preservation, transplant logistics and transplant-service support.
TransMedics Group, Inc. (Nasdaq: TMDX) has announced a public offering of 5,000,000 shares of common stock at $14.00 per share, aiming for gross proceeds of $70 million. The offering is anticipated to close on May 29, 2020, subject to customary conditions. An additional 750,000 shares may be purchased by underwriters within 30 days. J.P. Morgan and Morgan Stanley lead the offering, with SEC registration effective since May 21, 2020. This initiative supports TransMedics' mission to enhance organ transplant therapies.
TransMedics Group, Inc. (TMDX) announced a public offering of $60 million in common stock, with J.P. Morgan and Morgan Stanley as joint lead managers. The offering may include an additional 15% to be purchased by underwriters. The effective shelf registration statement was filed with the SEC on May 21, 2020. This offering aims to enhance the company's capabilities in organ transplant technologies, addressing the need for improved organ preservation and viability assessment. Investors are cautioned regarding potential risks that may affect the offering's completion.
TransMedics (TMDX) announced positive results from its U.S. Pivotal OCS Liver PROTECT Trial, achieving primary and secondary endpoints related to liver transplantation. The trial demonstrated significantly lower early allograft dysfunction (17.3% OCS vs. 30.5% Control, p=0.009) and a high 30-day patient survival rate of 99.3%. Additionally, ischemic cholangiopathy incidences were reduced (1.4% OCS vs. 8.5% Control, p=0.005). A total of 155 donor livers were used, with a utilization rate of 98.1%. The trial's success marks a significant advancement in liver transplantation technology.